# Functional Training Mitigates Reduced Circulating Indole‐3‐Lactate Levels in Persons With Relapsing–Remitting Multiple Sclerosis

**Authors:** Tiffany Wences Chirino, Frederike Adammek, Sergen Belen, Matteo Winker, Sebastian Proschinger, Annette Rademacher, Marit L. Schlagheck, Alexander Schenk, Marie Kupjetz, David Walzik, Clemens Warnke, Marcel Reuter, Friederike Rosenberger, Tim Meyer, Adrian McCann, Per Magne Ueland, Niklas Joisten, Philipp Zimmer

PMC · DOI: 10.1111/apha.70166 · 2026-01-28

## TL;DR

Functional training in people with multiple sclerosis increases a brain-protecting compound linked to gut health.

## Contribution

Shows that both short-term and long-term exercise can boost indole-3-lactate levels in MS patients.

## Key findings

- RRMS patients had lower baseline ILA levels compared to healthy controls.
- A 10-week training program increased the ILA/IAA index, indicating a neuroprotective effect.
- A single exercise session acutely raised ILA and ILA/IAA levels.

## Abstract

Indoles are tryptophan (Trp)‐derived metabolites that are produced by the gut microbiota and may influence the gut‐microbiota‐brain axis in multiple sclerosis (MS). Indole‐3‐lactate (ILA) is reduced in persons with MS and improves MS clinical scores in animal models via its anti‐inflammatory remyelinating properties. The ILA/indole‐3‐acetate (IAA) (ILA/AA) index is considered a neuroprotection index. Physical exercise and diet can modify gut microbiota and indole metabolism.

This secondary analysis of a randomized control trial aimed to assess the effects of acute and chronic exercise on serum indoles in relapsing–remitting MS (RRMS). Thirty‐one RRMS patients (≥ 70% session attendance) completed a 10 week multimodal functional training (60 min, 3×/week) vs. a waitlist control group. Blood samples were collected at baseline and compared to a matched healthy control group, and after 10 weeks for the assessment of chronic effects. Additionally, acute effects of a single bout of exercise were assessed with a blood sample before, during, and immediately after one interim training session. Serum indole concentrations were measured using LC–MS/MS.

Baseline indole levels in RRMS patients differed from those of matched healthy controls, and reduced ILA levels were observed. The 10 week intervention increased the ILA/IAA index, while a single exercise bout induced an increase in both ILA and ILA/IAA.

Multimodal functional training over 10 weeks led to an improved ILA/IAA index suggesting a neuroprotective shift in gut microbiota composition, and a single bout acutely increases the circulating level of ILA. Study registration number: DRKS00017091.

## Linked entities

- **Chemicals:** tryptophan (PubChem CID 1148), indole-3-lactate (PubChem CID 9548603), indole-3-acetate (PubChem CID 801)
- **Diseases:** multiple sclerosis (MONDO:0005301), relapsing–remitting multiple sclerosis (MONDO:0005314)

## Full-text entities

- **Genes:** Cyp1a1 (cytochrome P450, family 1, subfamily a, polypeptide 1) [NCBI Gene 13076] {aka AHH, AHRR, CP11, CYPIA1, P450-1}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, ACD (ACD shelterin complex subunit and telomerase recruitment factor) [NCBI Gene 65057] {aka DKCA6, DKCB7, PIP1, PTOP, TINT1, TPP1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AHR (aryl hydrocarbon receptor) [NCBI Gene 196] {aka FVH3, RP85, bHLHe76}, AWAT2 (acyl-CoA wax alcohol acyltransferase 2) [NCBI Gene 158835] {aka ARAT, DC4, DGAT2L4, MFAT, WS}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, IL4I1 (interleukin 4 induced 1) [NCBI Gene 259307] {aka FIG1, LAAO, LAO, hIL4I1}, Ahr (aryl-hydrocarbon receptor) [NCBI Gene 11622] {aka Ah, Ahh, Ahre, In, bHLHe76}, Il22 (interleukin 22) [NCBI Gene 50929] {aka IL-22, IL-22a, ILTIFa, If2b1, Iltif}, Cyp1a2 (cytochrome P450, family 1, subfamily a, polypeptide 2) [NCBI Gene 13077] {aka CP12, CYPIA2, P450-3}, CLEC3B (C-type lectin domain family 3 member B) [NCBI Gene 7123] {aka MCDR4, TN, TNA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TDO2 (tryptophan 2,3-dioxygenase) [NCBI Gene 6999] {aka HYPTRP, TDO, TO, TPH2, TRPO}, Cyp1b1 (cytochrome P450, family 1, subfamily b, polypeptide 1) [NCBI Gene 13078] {aka CP1B, CYPIB1, P4501b1}, CYP2E1 (cytochrome P450 family 2 subfamily E member 1) [NCBI Gene 1571] {aka CPE1, CYP2E, P450-J, P450C2E}
- **Diseases:** demyelination (MESH:D003711), neuroinflammation (MESH:D000090862), TSD (MESH:D013661), cancer (MESH:D009369), spinal cord demyelination (MESH:D020278), EAE (MESH:D004681), neurological diseases (MESH:D020271), Coronavirus Disease 2019 (MESH:D000086382), pwMS (MESH:D009105), overweight (MESH:D050177), ischemia (MESH:D007511), cardiovascular or orthopedic diseases (MESH:D002318), mesenteric ischemia (MESH:D065666), RRMS (MESH:D020529), colorectal cancer (MESH:D015179), MS (MESH:D009103), reperfusion injury (MESH:D015427), Huntington's disease (MESH:D006816), astrogliosis (MESH:D005911), inflammation (MESH:D007249)
- **Chemicals:** PCT (MESH:D011080), IPyA (MESH:C008122), teriflunomide (MESH:C527525), Ficoll (MESH:D005362), kynurenine (MESH:D007737), glatiramer acetate (MESH:D000068717), IAM (MESH:C015950), Trp (MESH:D014364), Neopterin (MESH:D019798), cuprizone (MESH:D003471), acetonitrile (MESH:C032159), IAld (MESH:C012381), IAA (-), Indole (MESH:C030374), vancomycin (MESH:D014640), ammonia (MESH:D000641), IAA (MESH:C030737), 3-indoxyl sulfate (MESH:D007200), indole-3-propionate (MESH:C000723775), DMT (MESH:D004130), Indoles (MESH:D007211), ILA (MESH:C024139), oxygen (MESH:D010100), Trypan Blue (MESH:D014343)
- **Species:** Limosilactobacillus reuteri (species) [taxon 1598], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12852534/full.md

---
Source: https://tomesphere.com/paper/PMC12852534